1. The 5-HT(7) receptor as a mediator and modulator of antidepressant-like behavior.
- Author
-
Sarkisyan G, Roberts AJ, and Hedlund PB
- Subjects
- Animals, Antipsychotic Agents pharmacology, Aripiprazole, Corticosterone blood, Depression genetics, Disease Models, Animal, Dopamine Uptake Inhibitors pharmacology, Dose-Response Relationship, Drug, Drug Synergism, Hindlimb Suspension methods, Male, Mice, Mice, Inbred C57BL, Mice, Knockout, Motor Activity drug effects, Phenols pharmacology, Piperazines pharmacology, Quinolones pharmacology, Receptors, Serotonin deficiency, Serotonin Antagonists pharmacology, Sulfonamides pharmacology, Swimming psychology, Antidepressive Agents pharmacology, Citalopram pharmacology, Receptors, Serotonin metabolism
- Abstract
The 5-HT(7) receptor has been suggested as a target for treating depression since inactivation or blockade of the receptor has an antidepressant-like behavioral effect. The present study investigated possible interactions between various classes of drugs with antidepressant properties and blockade or inactivation of the 5-HT(7) receptor. Immobility despair in the tail suspension test and the forced swim test was evaluated in mice lacking the 5-HT(7) receptor (5-HT(7)(-/-)) and in wild-type controls (5-HT(7)(+/+)) following acute drug treatments. Citalopram, a selective serotonin reuptake inhibitor and widely used antidepressant, dose-dependently reduced immobility in the tail suspension test in both 5-HT(7)(+/+) and 5-HT(7)(-/-) mice. Combining doses of citalopram and the 5-HT(7) receptor antagonist SB-269970 that by themselves did not affect behavior, reduced immobility in 5-HT(7)(+/+) mice in both the tail suspension test and the forced swim test. No effect was seen in 5-HT(7)(-/-) mice. Desipramine and reboxetine, two norepinephrine reuptake inhibitors, dose-dependently reduced immobility in the tail suspension test in 5-HT(7)(+/+) mice, but had no effect in 5-HT(7)(-/-) mice. A synergistic effect between desipramine and SB-269970 was found in both behavioral tests in 5-HT(7)(+/+) mice. Reboxetine combined with SB-269970 had effect only in the forced swim test. GBR 12909, a dopamine reuptake inhibitor, dose-dependently reduced tail suspension test immobility in both genotypes. There was no interaction between GBR 12909 and SB-269970. Aripiprazole, an antipsychotic, reduced immobility in both tests in 5-HT(7)(+/+) mice, but not in 5-HT(7)(-/-) mice. The results show that the 5-HT(7) receptor is required for the observed interaction between this receptor and antidepressants such as citalopram. The data furthermore support the hypothesis that the 5-HT(7) receptor might be a suitable target for treating depression.
- Published
- 2010
- Full Text
- View/download PDF